Alexander Perl

29PUBLICATIONS

135CO-AUTHORS

Haematological tumoursMolecular targetsQuantum optics and quantum optomechanicsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (29)

Sort by Publication Date:

|Jul 13, 2026

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

|Jun 01, 2026

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|Apr 08, 2026

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

|Oct 06, 2025

FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Mark J Levis, Harry P Erba, Pau Montesinos

|Jul 01, 2025

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Mark J Levis, Mehdi Hamadani, Brent R Logan

|May 07, 2025

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Martha L Arellano, Michael J Thirman, John F DiPersio

Pageof 5

Frequent Collaborators

11 joint publications

Mark Levis

Mark R Litzow

Jason Hill

Hee-Je Kim

Yi-Bin Chen

Masumi Ueda Oshima

Celalettin Ustun

Mehdi Hamadani

Pau Montesinos

Christine M McMahon

Frequent Collaborators

11 joint publications

Mark Levis

7 joint publications

Mark R Litzow

6 joint publications

Jason Hill

5 joint publications

Hee-Je Kim